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ABSTRACT
Cholecalciferol, the precursor of Vitamin D3, is a very old, high-
ly conserved, molecule. Its presence is evident in non-minera-
lized 750 million-year-old living species, such as plankton. The
more active metabolites, a receptor and a D binding protein,
appear later, along with the increasing complexity of animal
species living in the sea. In the sea, however, the biological
function of vitamin D is unlikely to be linked with mineral
metabolism, and we can hypothesize a relationship with an
immune response. It is in terrestrial animals exhibiting cellular
bone that the complexity of vitamin D increases. At this stage of
evolution, we see the appearance of bone cells that are capable
of producing hormones that regulate and are regulated by
vitamin D. This interaction starts a sophisticated metabolic
system that modulates both mineral and energy metabolism
for the requirements of the musculoskeletal system. Among
the so-called pleiotropic effects of vitamin D, those resulting
from the inhibitory effect on the renin-angiotensin system are
of particular interest for nephrologists. Intriguingly, however,
more than for anti-hypertensive effects, this interaction could
be relevant for anti-inflammatory actions, possibly representa-
tive of a residual ancestral role of vitamin D. In addition, this
evolutionary dynamism of the vitamin D system should not
be separated from the chemical dynamism that characterizes
the ligand molecule and its specific receptor. Both are capable
of significant tridimensional modifications that contribute
to an increase in the variability and the partial predictability
of their final biological effect. A dynamic overview of this sys-
tem that takes into account its evolutionary and adaptive
aspects may be helpful to understand its biological complexity
and to envisage why using vitamin Dmetabolites for therapeutic
purposes is still a matter of debate.
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INTRODUCTION
The number of publications on vitamin D is constantly in-
creasing and numbered over 4000 in 2014. The explanation
for this increasing interest stems from the accumulative
knowledge of this vitamin’s mechanisms of action and from
the parallel increase of potential clinical applications. Discov-
ered as an anti-rachitic compound, vitamin D still represents
the emblematic vitamin that fixes calcium to bone. However,
epidemiologic and experimental data allow us to hypothesize
numerous extra-skeletal effects [1]. Moreover, in recent
years, we have begun to regard vitamin D as not just a simple
vitamin but as a hormone and component of a sophisticated
‘vitamin D endocrine system’ that includes, besides the active
hormone (calcitriol), specific enzymes, a number of meta-
bolites, a definite receptor, a dedicated plasma transport
protein and hormones regulating vitamin D synthesis and
catabolism [2].
The aim of this review is to provide an evolutionary perspec-
tive of this hormone to help visualize how its biological and bio-
chemical dynamisms could have been relevant for its
transformation. It is necessary to note that the term vitamin
D refers to any compound with the biological activity of
1,25-dihydroxyvitamin D and encompasses both vitamin D3
(cholecalciferol, typical of animal life) and ergocalciferol (vita-
min D2, typical of vegetal life). In this paper we will refer, unless
specified, to the compound of animal origin and its natural
metabolites.
© The Author 2015. Published by Oxford University Press
on behalf of ERA-EDTA. All rights reserved.
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THE EVOLUTION OF VITAMIN D
We can find the precursor of vitamin D3, 7-deydrocholesterol
or pro-vitamin D3, in very old living organisms, such as plank-
ton. This allows dating its origin back to some 750million years
ago (MYA). The synthetic pathway of this precursor is much
conserved, being shared with cholesterol. We can in fact assimi-
late pro-vitamin D3 to a cholesterol molecule without two
hydrogens (Figure 1A). This resemblance allows us to hypothe-
size that in unicellular organisms, similar to cholesterol, vita-
min D3 was a component of the plasma membrane. However,
a specific feature characterizes this pro-vitamin D3: the capacity
of absorbing UV-B rays in the same wavelength of DNA. For
this reason, the biological role of pro-vitamin D3 in ancient or-
ganisms could have been that of protecting DNA from the toxic
effects of UV-B rays, rather than regulating Ca metabolism [3].
After UV-B ray absorption, pro-vitamin D3 is transformed into
the thermodynamically unstable pre-vitamin D3, which requires
afinal transformation into themore stable cholecalciferol or vita-
min D3 (Figure 1B). As such, this new molecule could be re-
garded as an inactivated end-product; however, in very old
organisms like algae, it is capable of promoting growth activity,
which points to the persistence of some biological effect [4].
Similar to cholecalciferol, the specific enzymes capable of
producing hydroxylated metabolites appear early in evolution,
in yeasts and old plants that have no calcified structure. A role
for vitamin D in the process of mineralization can be seen some
550MYA in snails and crustaceans, in which 25-hydroxyvitamin
D (25OHD3) [5] and 1,25-dihydroxyvitamin D [1,25(OH)2D3]
[6] could have some implication in the mineralization processes
(Figure 2).
Later in evolution, in jawless fishes that possess a type of vita-
min D receptor (VDR), the complexity of the vitamin D system
increases slightly. In these cartilaginous (non-calcified) fishes,
however, this ancestral receptor is involved in xenobiotic de-
toxification—a type of immune response—and not with calci-
fication [7] (Figure 2). It is in teleosts with cellular and
remodelling bone that VDR activation, for the first time, is in-
volved with calcium and phosphate absorption and bone min-
eralization [8]. It is subsequently in terrestrial animals that the
VDR becomes functionally divergent from that of aquatic ani-
mals by acquiring more definite ‘calcium-phosphate-oriented’
effects [9].
Along with the VDR, in vertebrates a specific vitamin D
binding protein (DBP) also appears seemingly functional to
the need of systemic transportation of the hydrophobic vitamin
F IGURE 1 : (A) 7-dehydrocholesterol, or pro-vitamin D3, shares the synthetic pathway with cholesterol, from which it differs by the absence of
two hydrogen atoms. (B). Following UV-B ray absorption, the B ring of pro-vitamin D3 opens, thus becoming pre-vitaminD3. The newmolecule is
unstable and prone to transform into vitamin D3, by simply rotating around the C6–C7 single bond.
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Dmetabolites [10] (Figure 2). This protein has a specific ligand
binding domain (LBD) for vitaminDmetabolites and circulates
in excess amounts compared with ligands, thus representing a
storage compartment. Further, it has different affinity for each
of the vitamin Dmetabolites [e.g. 600 times higher for 25OHD3
than for 1,25(OH)2D3] and in this way regulates circulating le-
vels of the free fractions of each metabolite [10].
In parallel with DBP appearance, a feedback system suppres-
sing 1,25(OH)2D3 synthesis when VDR is activated becomes
manifest [11]. The complexity of this system illustrates how
tightly regulated are calcitriol levels, whose free circulating frac-
tion is the one that is biologically active but, at the same time,
also more susceptible to catabolism.
We can thus consider that many components of the vitamin
D system (metabolites, enzymes, receptors and binding pro-
teins) are present in early fishes but with an unlikely role in cal-
cium homeostasis. In fact, plenty of calcium has been available
in seawater (some 40 mg/dL) since at least the Cambrian explo-
sion (the biological era characterized by an exponential increase
in the number of life species in the sea). According to an evo-
lutionary hypothesis, an increase in calcium concentration
in seawater (secondary to rock dissolution) preceded the
Cambrian era and was determinant for the explosion in the
number of life species [12]. Accordingly, defensive or detoxify-
ing roles are the most probable functions of vitamin D in more
simple life species in the sea. Involvement with bone and min-
eral homeostasis seems to start in more evolved aquatic bony
fishes and becomes progressively more evident later in terres-
trial animals with cellular and remodelling bone. In these
animals, the interaction with bone cells is a determinant for
vitamin D to acquire a systemic role (Figure 2). A fine-tuned
calcium regulation mechanism becomes evident through inte-
grated activation of VDRs not only in bone but also in intestinal
and renal cells, also thanks to cooperation with parathyroid
hormone (PTH), PTH-related peptide and calcitonin, whose
origin and evolution is still not settled. We know however,
that PTH-like peptides are first present in cartilaginous fishes,
suggesting roles unrelated to bone formation and an origin suc-
cessive to vitamin D [13]. In any case, a considerable increase
in the complexity of the vitamin D system became evident
with the discovery that by interacting with bone cells, vitamin
D regulates not only the process of mineralization but also the
synthesis of two hormones, fibroblast growth factor 23 (FGF23)
and osteocalcin (OC), which both have relevant metabolic
actions [14].
FGF23 originates in early vertebrates from the duplication
of the ancestral canonical FGF gene [15] and is mainly pro-
duced by osteocytes. It is an essential phosphate and vitamin
D-regulating hormone, which lowers both phosphate and
1,25(OH)2D3 serum concentrations. Since 1,25(OH)2D3 can
stimulate osteocyte synthesis of FGF23, a feedback system is
clear. FGF23 null animals develop hyperphosphataemia, in-
creased 1,25(OH)2D3 levels, hypercalcaemia, diffuse ectopic
calcifications and premature aging [16]. This phenotype
F IGURE 2 : Accrual of the vitamin D system components along with the evolution of species. Notably, the appearance of secreting bone cells
renders the system sophisticated and involved with mineral and energy metabolism. In addition, Klotho appearance antedates that of FGF23 by
roughly 100 MY.
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overlaps with that of Klotho null mice. In fact, Klotho is a
co-receptor of FGF23, responsible for imparting tissue-specific
affinity and sensitivity to FGF receptors. The complete biologic-
al relevance of the FGF23/Klotho system is still not settled and
could possibly go beyond mineral metabolism, since direct car-
diac effects have been demonstrated for both FGF23 [17] and
Klotho [18] in experimental conditions and in renal patients
[17]. Further, by regulating renal tubular Na-Cl co-
transporters, FGF23 may influence blood volume and pressure
[19]. In any case, it is deeply linked with vitamin D regulation
and can be considered part of the vitamin D system.
OC, which first appeared in bony vertebrates [20], definitely
represents another important endocrine function of the bone.
Since its discovery, and due to the presence in its molecule of
three γ-carboxylated glutamic acid residues that avidly bind cal-
cium, OC has been considered a bone protein involved with
mineralization processes. However, OC null mice show in-
creased bone mass without mineralization defects in front of
a clear phenotype of diabetes-obesity [21]. In fact, we now
know that a metabolite of OC, undercarboxylated OC, which
is mainly produced during bone resorption, stimulates insulin
secretion by the pancreatic β-cells and promotes insulin sensi-
tivity in peripheral organs while also modulating adipocyte ac-
tivity [22]. Importantly, by stimulating its own receptor on
osteoblasts, insulin inhibits the synthesis of osteoprotegerin in
these cells, thus increasing osteoclast recruitment, bone resorp-
tion and further OC production (feed-forward feedback). Vita-
min D, which regulates bone cells in general and can either
stimulate transcription [23] or reduce circulating levels of OC
[24], is thus involved with energy metabolism [25].
Further to FGF23 and OC, vitamin D has inhibitory effects
on the bone synthesis of a protease-resistant circulating factor,
the acidic serine aspartate rich MEPE-associated motif
(ASARM). This peptide derives from the shedding of a motif
from any of the small integrin-binding ligand N-linked glyco-
proteins (SIBLINGs), which is a special family of bone proteins.
While the SIBLINGs are essential for regular mineralization of
the extracellular matrix of bone and teeth [26], ASARM circu-
lating peptide is a powerful inhibitor of mineralization. In add-
ition, ASARM peptide can reduce the pH of the local matrix,
thus favouring the production of undercarboxylated OC in
the lacunae of bone resorption. We can regard the SIBLINGs
and ASARM peptide as the most recently discovered compo-
nents of the vitamin D endocrine system contributing to
strengthen the link between bone and energy metabolism [27].
In summary, through a complex interaction with bone cells
vitamin D becomes part of a broader metabolic regulatory sys-
tem. In these cells vitamin D regulates several receptors and en-
zymes [like its own receptor, receptor activator of NF-κB ligand
(RANKL), low-density lipoprotein receptor-related protein 5
(LRP5) and cystathionine B-synthase (CBS) among others]
but also two bone hormones. From an evolutionary point of
view, this hormonal interaction with bone marks a notable
step in the evolution of vitamin D system as it moves progres-
sively along with more complex animal species (Figure 2). This
most probably reflects the necessary evolution and adaptation
for life on Earth. Migration of living organisms from sea to land
represented, in fact, a gigantic challenge. Prompt availability of
calcium, which is abundant in the sea but scarce on land, was
critical, and a storage organ, like bone, was necessary. On land,
thanks to the cooperation with muscles, bone also allowed
walking and running, which are essential to increase the prob-
ability of survival. Bones, which are packed with very active
energy-requiring cells, and muscles—the musculoskeletal sys-
tem—are an energy-expensive structure in need of a peculiar
endocrine system capable of regulating extracellular mineral
ion concentrations and energy metabolism at the same time.
With its regulatory effects on bone cells, vitamin D represents
a component of such a powerful and sophisticated system [28].
VITAMIN D PLEIOTROPISM
Vitamin D status is commonly assessed by serum levels of
the metabolite 25OHD3, which reflects storage better than
1,25(OH)2D3. Optimal levels are not unanimously defined,
but most experts agree that values <20 ng/mL indicate defi-
ciency, values between 21 and 29 ng/mL indicate relative insuf-
ficiency and levels >30 ng/mL sufficiency [29]. With these
limits, vitamin D insufficiency is increasingly appreciated in
general and pathologic populations and the potential clinical
consequences are feared.
In fact, besides the classical undisputed actions resulting
from VDR activation in the intestine, bones and kidneys, vita-
min D also has pleiotropic effects. In mammals, many tissues
express VDR and, most importantly, numerous cell types in a
variety of organs possess vitaminD hydroxylases allowing local,
autocrine/paracrine production of active vitamin D metabo-
lites. This gives a biological plausibility to vitamin D’s claimed
various non-skeletal health benefits. Indeed, observational
studies link vitamin D deficiency with chronic illnesses like
diabetes, cancer, infections, cardiovascular and autoimmune
diseases. Experimental studies indicate, for example, that vita-
min D may have favourable effects on prostate cancer cells
through anti-proliferative effects (by modulation of Kreb’s
cycle, in an androgen-dependent way) [30] and pro-differentiating
effects (by enhancement of gap junction formation) [31]. How-
ever, evidence for a protective role of adequate vitamin D intake
is more convincingly established for rickets/osteomalacia [32]
and osteoporotic fractures [33] than for falls [34] or premature
mortality [35]. There is much less evidence for beneficial effects
on cancer, infections, autoimmune or cardiovascular diseases, al-
though this could be due to the existence of different therapeutic
target levels for each disease [36].
Among the so-called pleiotropic effects of vitamin D, one
possibly linked with evolution is the relationship with the
renin-angiotensin system (RAS). Li et al. [37] unambiguously
demonstrated this link in a model of VDR null mice character-
ized by hyperplasia of the macula densa and hyper-reninism.
Since then the biological plausibility of observational studies re-
porting a negative association between vitamin D status and
hypertension has increased. Actually, however, the clinical rele-
vance of the association remains rather weak since a recent
meta-analysis concluded that vitamin D supplementation is in-
effective for lowering blood pressure [38]. Notwithstanding this
argument, the link between vitamin D and RAS could be
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intriguing in a different way. The RAS is present in primitive
animals that do not have a circulatory system, thus excluding
a regulatory role on blood volume or pressure [39]. Alternative-
ly, a pro-inflammatory effect of RAS is quite possible in these
animals. Angiotensin I receptors, responsible for the biological
effects of RAS, are expressed in several different tissues not in-
volved with blood pressure regulation and can be found, in par-
ticular, in the mitochondria. Activation of these receptors
increases oxidant production and reduces mitochondrial life-
span thus promoting inflammation and cellular aging [40].
On the other hand, we know that activation of VDRs, which
are similarly detectable in mitochondria [41], result in anti-
inflammatory effects through inhibition of reactive oxygen spe-
cies and NF-κB synthesis [42]. Intriguingly, during evolution,
VDR and RAS appear contemporarily in many animal species.
Thus, according to Ferder et al. [43] it is possible to hypothesize
that, in very old animals, vitamin D and RAS were antagonistic
systemsmodulating the inflammatory response—i.e. an ancient
type of immune response. Both systems evolved to acquire spe-
cialized functions essential for life on Earth. In fact, blood vol-
ume and pressure (necessary to circulate internal water) and
bone (necessary to guarantee adequate ions and energy supply)
are both essential for life on land. So it seems that when search-
ing for pleiotropic effects of vitamin D or for non-blood
pressure-related effects of RAS, we are in fact exploring ancient
functions of these two systems. To what extent we will succeed
in using these ancient properties for clinical purposes is still an
open question warranting further research.
CHEMICAL AND BIOCHEMICAL DYNAMISM
OF VITAMIN D AND ITS RECEPTOR
The chemical properties of the vitamin D3 molecule are unique
compared with parent sterol ligands (e.g. oestrogens), similarly
capable of inducing genomic and non-genomic effects by acting
on the same receptor [44]. In fact, while other sterols have rigid
molecular structures, vitamin D3 should be seen as a dynamic
molecule capable of quickly sampling numerous different con-
formations, resulting in different tridimensional shapes [45,
46]. This dynamism, which, as illustrated later, also involves
the VDR, allows explanation of how vitamin D metabolites or
synthetic analogues may elicit somewhat different responses by
activating the same receptor.
The dynamism of the molecule starts with the UV-B-induced
opening of the B ring that prompts the A ring to rotate around
the C6–C7 single bond and give rise to vitamin D3 (Figure 1B).
In the new molecule, the central C-D ring is regarded as rigid
(the rigid backbone) but the A ring and the side chain are def-
initely flexible. The A ring, by freely rotating above and below
the C-D ring plain, adapts to either cis- or trans-conformations
[47]; it may also change into two further shapes, called α-chair
or β-chair [48]. The side chain, which is the most dynamic re-
gion, can rotate 360 degrees around the single bond that links it
to the C-D ring, and each carbon of the chain also has some
flexibility (Figure 3). The number of tridimensional conforma-
tions that a metabolite can sample is thus very high and
F IGURE 3 : VitaminD3molecule is characterized by unique dynamic properties and can sample numerous tridimensional shapes. Also, different
functional roles can be recognized in the three different parts of this ligand. DBP = vitamin D binding protein; IC-DBP = intracellular DBP.
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interconversion of shapes occur millions of times per second.
For example, the twomost powerful metabolites among the nu-
merous natural vitamin D sterols, namely 25OHD3 and 1,25
(OH)2D3, are also the most conformationally dynamic [49].
Importantly, modifications occurring in the carbon scaffold
(e.g. hydroxylation, methylation, etc.) will decrease or increase
the number of possible tridimensional conformations that the
molecule can sample, thus affecting its biologic activity. In fact,
as an example, both 25OHD3 and 1,25(OH)2D3 interact with
the VDR, but due to a more precise stereospecific binding,
the second is much more powerful. Nonetheless, 25OHD3
also has specific biologic effects, which have been claimed for
many years and confirmed, even recently, to occur through
VDR activation [50]. Further, since as illustrated in Figure 3, spe-
cific regions in the vitamin D molecule have specific functions
[49, 51, 52], we can predict that changes in the shape of the mol-
ecule in one of these regions will modify a specific step in the vita-
min D metabolism or receptor interaction. It is thus accepted that
conformational flexibility is one of the components of the physico-
chemical and biologic properties of each vitamin D metabolite.
To exert their genomic effect ligands need to interact not just
with the VDR, but also with other proteins (RXR-co-receptor,
activator and repressor complexes) that are determinants of
the final effect. Notably, ligand interaction with the VDR pro-
duces critical conformational receptor changes that are rele-
vant, as illustrated below, for the eventual activation process
of this complex cascade that has been renamed ‘the VDR
machine’.
In the VDR, similar to the ligandmolecule, we recognize dif-
ferent structural and functional portions: LBD, connective
hinge, DNA-binding domain (DBD) and A/B domains, each
with specific roles in the steps leading to the genomic effects
(Figure 4A). The LBD, which is critical for interaction with vita-
min D, contains in its internal portion the so-called ligand
binding pocket (LBP), into which the ligand will lodge. This
pocket contains specific anchoring points and conformation-
ally adapts to the ligand, the final shape being different and spe-
cific for each individual ligand (Figure 4B) [53]. The specific
ligand-induced conformational modification of the LBP even-
tually affects the shape of the whole VDR, thus becoming a
further variable in the activation of the VDR machine. In fact,
the final shape of the activated receptor is responsible for the
stability and selectivity of the interactions with the proteins
(RXR-co-receptor, co-repressors and/or co-activators), which
are an essential component of the machine. Since the VDR is
expressed in cells of different tissues, the repressor or activator
protein-complexes will be different and have a different affinity
for the activated receptor, thus increasing the variability of the
response (Figure 5A and B). The importance of this shape
modification has been exploited by the industry to develop
some 3000 synthetic analogues of vitamin D, with more select-
ive biological properties than natural compounds.
Vitamin D and VDR dynamism are also invoked by some
authors to explain how either genomic or non-genomic effects
can be elicited following the activation of the same receptor pro-
tein [54]. In fact, a synthetic analogue characterized by the A
ring locked in cis-position has been shown to exert almost
exclusively rapid (non-genomic) effects, suggesting that this
naturally occurring conformation might be the one responsible
for this type of effect [55].
There is one last consideration to make about the dynamism
of vitamin D and its receptor: when we try to recreate any of the
F IGURE 4 : Schematic of the VDR. (A). Different functional domains are present in the VDR. (B). Interaction with the ligand changes the shape
of the LBD into a different one, specific of each potential ligand.
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three-dimensional modelling of their interaction, we are actual-
ly taking a single picture of the whole film occurring in vivo.
CONCLUSIONS
Vitamin D should be regarded as a very conserved molecule
that probably started as a component of the plasma membrane
of simple organisms, with protective or defensive roles. Its func-
tion has changed to become a necessary regulatory element of
the metabolic and energetic requirements of life on Earth. The
dynamism of the molecule and its receptor certainly represents
an element of the plasticity that allowed the acquisition of such
highly specialized properties within themusculoskeletal system.
It is impressive that during evolution the appearance of cellular
bone increases the complexity of the system, with the produc-
tion of bone proteins that counter-regulate the effects of vita-
min D on bone and muscles. Significantly, the VDR, possibly
because of its ancestral biological roles, is present in numerous
tissues not necessarily involved with the musculoskeletal sys-
tem. Among the claimed pleiotropic properties, the systemic
but generic anti-inflammatory effects could be related to the
RAS-inhibitory properties. Given this complex biology, it
seems rather simplistic to try to deduce its function through
the assay of one or two blood circulating metabolites. A dynam-
ic view of the interaction with its receptor is certainly helpful to
try to understand why we cannot exactly predict the biological
effects of the natural compounds. In fact, the recommended
doses of this ‘vitamin’ either for healthy people or for patients
are still a matter of debate. A dynamic view also helps to under-
stand why synthetic analogues can have very specific biologic
effects and can be considered for very different clinical purposes
(from cancer to infection) through activation of the same recep-
tor. Vitamin D and its receptor should be regarded as a rather
sophisticated molecular machine that we are still discovering.
Much more remains to be discovered, but a general overview
that takes into account the evolutionary aspects of this system
seems useful to try to understand the multifaceted biology of
this ‘vital amine’.
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